The self-made Kangxianfang in treating patients with hepatic fibrosis of chronic hepatitis B and its influence on Th1/Th2 cell subsets in patients
-
摘要: [目的]探讨自拟抗纤方治疗慢性乙型肝炎肝纤维化患者的疗效及对患者Th1、Th2细胞亚群的影响。[方法]102例慢性乙型肝炎肝纤维化患者依据随机数字表法随机分为观察组51例与对照组51例。对照组采用常规西药治疗,观察组在对照组基础上结合自拟抗纤方治疗。2组疗程均为6个月。比较两组疗效、肝功能指标、门静脉内径、脾脏厚度、IFN-γ、IL-4水平及不良反应发生情况。[结果]观察组总有效率(92.16%)高于对照组(74.51%)(P＜0.05);2组肝功能指标AST、TBIL、ALT治疗后明显下降(P＜0.05);观察组肝功能指标AST、TBIL、ALT治疗后低于对照组(P＜0.05);2组门静脉内径、脾脏厚度治疗后减少(P＜0.05);观察组门静脉内径、脾脏厚度治疗后低于对照组(P＜0.05);2组IFN-γ治疗后增加,而IL-4下降(P＜0.05);观察组IFN-γ治疗后高于对照组,而IL-4低于对照组(P＜0.05);2组均未见严重用药不良反应。[结论]自拟抗纤方治疗慢性乙型肝炎肝纤维化患者的疗效显著,改善患者Th1、Th2细胞亚群水平,从而纠正Th1/Th2失衡,且安全可靠。
-
关键词:
- 自拟抗纤方 /
- 慢性乙型肝炎肝纤维化 /
- 疗效 /
- Th1/Th2细胞亚群
Abstract: [Objective]To investigate the self-made Kangxianfang in treating patients with chronic hepatitis B hepatic fibrosis and the effect on patients with Th1,Th2 cell subsets.[Methods]102 cases of chronic hepatitis B patients with liver fibrosis were randomly divided into observation group 51 cases and control group 51 cases.The control group received conventional western medicine treatment,the observation group in the control group received the combined anti-fibrosis treatment.The course of the two groups was 6 months.The effects of the two groups were compared in the indexes of liver function,portal vein diameter,spleen thickness,IFN-γ,IL-4 level and adverse reactions.[Results]The total effective rate in the observation group(92.16%)was higher than that in the control group(74.51%)(P＜0.05);ALT,TBIL and AST in the two groups were significantly decreased(P＜0.05);After treatment of observation group,AST,TBIL and ALT were lower than the control group(P＜0.05);Two groups of portal vein diameter,spleen thickness after treatment decreased(P＜0.05);The inner diameter of portal vein and spleen thickness in observation group were lower than those in control group(P＜0.05);The two groups increased after treatment with IFN-γ,while IL-4 decreased(P＜0.05);The observation group was higher than the control group after treatment with IFN-γ,and IL-4 was lower than that of the control group(P＜0.05);No serious adverse drug reactions were observed in the two groups.[Conclusion]the self-made Kangxianfang has significant efficacy in the treatment of chronic hepatitis B patients with liver fibrosis,improve patients with Th1,the level of Th2 cell subsets,thereby correcting the imbalance of Th1/Th2,which is safe and reliable. -
-
[1] 张国盛,王天懿,徐有青,等.实时组织弹性成像技术对慢性乙型肝炎肝纤维化的诊断价值[J].临床肝胆病杂志,2014,13(7):616-619.
[2] 方群,晋军,贾学明.超声实时组织弹性成像评估慢性乙型肝炎肝纤维化的临床应用价值[J].河北医学,2014,24(3):473-476.
[3] 肖作汉.扶正化瘀胶囊结合常规疗法治疗慢性乙型肝炎肝纤维化104例[J].上海中医药杂志,2014,60(2):29-30.
[4] 范瑞琴,苏传真,朱刚剑,等.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化73例疗效观察[J].胃肠病学和肝病学杂志,2013,22(1):31-33.
[5] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中国肝脏病杂志:电子版,2010,2(4):54-60.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:143-143.
[7] 董小平.替比夫定联合扶正化瘀片治疗慢性乙型肝炎肝纤维化60例疗效观察[J].临床肝胆病杂志,2013,29(9):689-691.
[8] 李仁国,胡鹏.血府逐瘀汤联合干扰素治疗慢性乙型肝炎肝纤维化疗效观察[J].陕西中医,2013,34(4):442-444.
[9] 吴亚玲.排毒抗纤扶正汤治疗慢性乙型肝炎纤维化疗效观察[J].实用临床医药杂志,2014,15(1):72-73.
[10] 韩曼珠,王芬,李丽,等.抗纤肝汤治疗慢性乙型肝炎肝纤维化54例[J].中国实验方剂学杂志,2015,(16):183-187.
[11] 方华珍,丁成华,程绍民,等.自拟化瘀抗纤汤治疗慢性病毒性肝炎肝纤维化的临床观察[J].时珍国医国药,2014,17(10):2430-2431.
[12] 车宏浩,赵彩彦,王亚东,等.慢性乙型肝炎肝纤维化患者Th1/Th2细胞及其细胞因子的变化[J].中华临床感染病杂志,2013,5(6):332-337.
-
计量
- 文章访问数: 55
- PDF下载数: 363
- 施引文献: 0
下载: